Deep neural network modeling based virtual screening and prediction of potential inhibitors for renin protein

被引:4
作者
Bhagwati, Sudha [1 ]
Siddiqi, Mohammad Imran [1 ]
机构
[1] Cent Drug Res Inst, CDRI, CSIR, Mol & Struct Biol Div, Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India
关键词
Activity prediction; deep neural network; MD simulation; molecular docking; QSAR; ANTIHYPERTENSIVE EFFICACY; FORCE-FIELD; ALISKIREN; DISCOVERY; IDENTIFICATION; GENERATION; SYSTEM; LIGAND;
D O I
10.1080/07391102.2020.1860825
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Renin enzyme plays an essential role in the Renin-Angiotensin System (RAS), and it is involved in the pathogenesis of hypertension and several other cardiovascular diseases (CVDs). Inhibition of renin is an effective way to intervene with the pathogenesis of these diseases. Docking-based virtual screening, 3D-Quantitative Structure-Activity Relationship (3D-QSAR), and structure-based drug design are the most frequently used strategies towards discovering novel inhibitors targeting renin. In this study, we have developed a 2D fingerprint-based Deep Neural Network (DNN) classifier for virtual screening and a DNN-QSAR model for biological activity prediction. The resulting hits from the DNN-QSAR model were then subjected to the molecular docking to identify further top hits. Molecular Dynamics (MD) simulation was conducted to get a better insight into the binding mode of identified hits. We have discovered six compounds from the Maybridge chemical database with the predicted IC50 values ranging from 24.2 nM to 83.6 nM. To the best of our knowledge, this is the first study that used a cascaded DNN model to identify potential lead compounds for the inhibition of renin target. Through the results presented in this study, we provide evidence of the DNN method being a useful approach to identify new chemical entities/novel lead compounds that may overcome the limitation of existing conventional strategies used in drug discovery research. Communicated by Ramaswamy H. Sarma
引用
收藏
页码:4612 / 4625
页数:14
相关论文
共 49 条
[1]   Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers [J].
Abraham, Mark James ;
Murtola, Teemu ;
Schulz, Roland ;
Páll, Szilárd ;
Smith, Jeremy C. ;
Hess, Berk ;
Lindah, Erik .
SoftwareX, 2015, 1-2 :19-25
[2]   Molecular modeling assisted identification and biological evaluation of potent cathepsin S inhibitors [J].
Ahmad, Sabahuddin ;
Bhagwati, Sudha ;
Kumar, Sushil ;
Banerjee, Dibyendu ;
Siddiqi, Mohammad Imran .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2020, 96
[3]   Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation [J].
Al-Nadaf, Afaf H. ;
Taha, Mutasem O. .
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2011, 29 (06) :843-864
[4]   The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[5]   Identification of potential soluble epoxide hydrolase (sEH) inhibitors by ligand-based pharmacophore model and biological evaluation [J].
Bhagwati, Sudha ;
Siddiqi, Mohammad Imran .
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (16) :4956-4966
[6]   Optimal classifier for imbalanced data using Matthews Correlation Coefficient metric [J].
Boughorbel, Sabri ;
Jarray, Fethi ;
El-Anbari, Mohammed .
PLOS ONE, 2017, 12 (06)
[7]  
Brown MJ, 2006, J RENIN-ANGIO-ALDO S, V7, pS7
[8]   The rise of deep learning in drug discovery [J].
Chen, Hongming ;
Engkvist, Ola ;
Wang, Yinhai ;
Olivecrona, Marcus ;
Blaschke, Thomas .
DRUG DISCOVERY TODAY, 2018, 23 (06) :1241-1250
[9]  
Chen Y, 2017, CLIN EXP PHARMACOL P, V44, P266, DOI [10.1111/1440-1681.2692, 10.1111/1440-1681.12692]
[10]   Brain RAS: Hypertension and Beyond [J].
de Gasparo, Marc ;
Speth, Robert C. ;
Baltatu, Ovidiu C. ;
Vanderheyden, Patrick .
INTERNATIONAL JOURNAL OF HYPERTENSION, 2013, 2013